Impact of Continuing Medical Education (CME) Insulin Program

This study has been completed.
Sponsor:
Collaborators:
International Diabetes Center at Park Nicollet
Eli Lilly and Company
Novo Nordisk A/S
United Health Care
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Park Nicollet Institute
ClinicalTrials.gov Identifier:
NCT00824603
First received: January 15, 2009
Last updated: August 22, 2013
Last verified: August 2013

January 15, 2009
August 22, 2013
June 2006
August 2009   (final data collection date for primary outcome measure)
We will determine whether attendees' self-reported confidence and use of insulin with persons with type 2 diabetes changes after they attend the CME program. [ Time Frame: pre program survey & 2-4 month post program survey ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00824603 on ClinicalTrials.gov Archive Site
pre-CME training level of patient's A1c when starting insulin therapy compared to post-CME training level of patient's A1c when starting insulin therapy [ Time Frame: pre program survey and 2-4 month post program survey ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Impact of Continuing Medical Education (CME) Insulin Program
Impact of CME Program on Self-Reported Confidence and Use of Insulin in Persons With Type 2 Diabetes

The purpose of this study is to determine if a continuing medical education (CME) program can change primary care providers' use of insulin therapy - their confidence in selecting doses and engagement of patients in the decision making as to whether to initiate insulin therapy.

We will determine whether attendees' self-reported confidence and use of insulin with persons with type 2 diabetes changes after they attend the CME program. Specifically, we will address the following questions:

Question 1. Clinical guidelines. Is insulin initiated earlier (at a lower A1C)?

Question 2. Decision-making. Does confidence in selecting a starting insulin regimen change? Does confidence in selecting a starting insulin dose change? Does confidence in adjusting insulin change? Does confidence in discussion nutrition guidelines change?

Question 3. Application. Do more patients start using insulin? Who usually selects starting dose? How is starting dose selected? How often is insulin adjusted?

Question 4. Resources. How available are protocols for insulin use? How available is adequate time to monitor insulin therapy? How available is staff to teach insulin injections? How available is staff to help adjust insulin?

Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Primary care providers affiliated with the participating healthcare organizations were invited to attend.

Diabetes
Not Provided
primary care provider
attending insulin CME Training
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
294
August 2009
August 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • primary care provider attending CME training

Exclusion Criteria:

-

Both
25 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00824603
03425-06-C
No
Park Nicollet Institute
Park Nicollet Institute
  • International Diabetes Center at Park Nicollet
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • United Health Care
  • Merck Sharp & Dohme Corp.
Principal Investigator: Margaret Powers, PhD International Diabetes Center at Park Nicollet
Park Nicollet Institute
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP